Bruce C. Robertson - Aug 3, 2021 Form 4 Insider Report for RxSight, Inc. (RXST)

Role
Director
Signature
/s/ Shelley Thunen, as Attorney-in-Fact
Stock symbol
RXST
Transactions as of
Aug 3, 2021
Transactions value $
$0
Form type
4
Date filed
8/5/2021, 07:48 PM
Previous filing
Jul 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXST Common Stock Conversion of derivative security $0 +1.39M $0.00 1.39M Aug 3, 2021 See footnote F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXST Series G Preferred Stock Conversion of derivative security $0 -968K -100% $0.00* 0 Aug 3, 2021 Common Stock 968K See footnote F1, F3
transaction RXST Series H Preferred Stock Conversion of derivative security $0 -403K -100% $0.00* 0 Aug 3, 2021 Common Stock 403K See footnote F2, F3
transaction RXST Warrant (right to buy) Options Exercise $0 -60.5K -100% $0.00* 0 Aug 3, 2021 Series H Preferred Stock 60.5K $12.40 See footnote F2, F3, F4
transaction RXST Series H Preferred Stock Options Exercise $0 +60.5K $0.00 60.5K Aug 3, 2021 Common Stock 60.5K See footnote F2, F3, F4
transaction RXST Series H Preferred Stock Tax liability $0 -46.9K -77.48% $0.00 13.6K Aug 3, 2021 Common Stock 46.9K See footnote F2, F3, F4
transaction RXST Series H Preferred Stock Conversion of derivative security $0 -13.6K -100% $0.00* 0 Aug 3, 2021 Common Stock 13.6K See footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Bruce C. Robertson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.
F3 All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F4 The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.